One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   T-Cell Lymphoma Market

[ 英語タイトル ] T-Cell Lymphoma Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0088629
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 116
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Biocryst Pharmaceuticals Inc.
- Bristol-Myers Squibb Company
- Genmab AS
- Johnson & Johnson (Janssen Pharmaceuticals Inc.)
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd
- Novartis International AG
- Autolus Therapeutics PLC
- Spectrum Pharmaceuticals

[Report Description]

Lymphoma is the most common blood cancer. It occurs when cells of the immune system, called lymphocytes (a type of white blood cells), grow and multiply uncontrollably in the human body. Certain factors that are driving the market growth include a rise in lymphoma cancer incidence due to radiations, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders. Cancerous lymphocytes can affect body parts, including the lymph node, spleen, bone marrow, blood, or other organs, and can form a mass called a tumor. The increase in cancer drug prices since the last 15 years has been a problem for the global population. Patients who have developed cancer may not be able to afford treatment, due to the high costs associated with it. Due to the high cost of treatment, it is very difficult for everyone to afford cancer therapies or drugs, which limits the market.

Key Market Trends

Chemotherapy is Expected to Show Better Growth over the Forecast Period

Lymphomas are generally classified as Hodgkin lymphoma and non-Hodgkin lymphoma, depending on the types of cells. T-cell lymphomas are non-Hodgkin lymphomas that develop from T lymphocytes. According to the American Cancer Society, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States that accounts for about 4% of all cancers. There are a variety of treatment options available for the treatment of T-cell lymphoma and leukemia. While surgery and radiation therapy are used to remove or kill cancer cells in a particular area, chemotherapy can act on the rapidly dividing cancer cells throughout the entire body. With intensive chemotherapy, the complete remission rate can be very high, and many patients can be cured. Chemotherapy for the treatment of T-cell lymphoma or leukemia may be delivered in several ways, such as intravenous, oral, and intrathecal. Hence, owing to these factors, the market is expected to witness significant growth in the future.

North America Dominates the Market and it is Expected to do the Same over the Forecast Period

According to the Lymphoma Research Foundation, T-cell lymphomas account for about 7% of all non-Hodgkin's lymphoma (NHL) in the United States, according to their Surveillance, Epidemiology, and End Results program. In addition, angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type, accounting for about 7-8% of all patients having T-cell lymphomas in the United States. Most patients have been found to be middle-aged to elderly, and they are diagnosed with advanced-stage disease. Several organizations are currently playing a significant role in spreading awareness regarding T-cell lymphoma across the region. For example, the Leukemia and Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, education, and patient services. Furthermore, due to these rising incidences in the United States, the T-cell lymphoma market is expected to grow during the forecast period.

Competitive Landscape

The market is highly competitive and consists of a few major players. Companies, like Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Genmab AS, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Merck & Co. Inc., Novartis, F. Hoffmann-La Roche Ltd, Autolus Therapeutics PLC, and Spectrum Pharmaceuticals, hold the substantial share in the market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Lymphoma Cancer Incidences
4.2.2 Increase in the Number of T-cell Lymphoma Specific Therapies
4.2.3 Risk of Lymphoma Due to Autoimmune Disorders
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Adverse Side Effects of Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Lymphoma
5.1.1 Peripheral T-cell Lymphoma
5.1.2 Cutaneous T-cell Lymphoma
5.1.3 Anaplastic Large Cell Lymphoma
5.1.4 Angio-immuno-blastic T-cell Lymphoma
5.1.5 Other Types of Lymphoma
5.2 By Type of Therapy
5.2.1 Radiotherapy
5.2.2 Chemotherapy
5.2.3 Other Types of Therapy
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Biocryst Pharmaceuticals Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Genmab AS
6.1.4 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
6.1.5 Merck & Co. Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Novartis International AG
6.1.8 Autolus Therapeutics PLC
6.1.9 Spectrum Pharmaceuticals




Recommended reports